phingomyelin synthase (SMS) sits at the crossroads of sphingolipid biosynthesis. Blockage of SMS activity should influence not only sphingomyelin (SM) and ceramide levels, but also those of other related sphingolipids, including glycosphingolipid, sphingosine, and sphingosine-1-phosphate. SMS has 2 isoforms: SMS1 and SMS2. Although both enzymes catalyze the same reactions, their subcellular localizations are different: SMS1 is found in the trans-Golgi apparatus, whereas SMS2 is predominantly found in the plasma membranes.
S
phingomyelin synthase (SMS) sits at the crossroads of sphingolipid biosynthesis. Blockage of SMS activity should influence not only sphingomyelin (SM) and ceramide levels, but also those of other related sphingolipids, including glycosphingolipid, sphingosine, and sphingosine-1-phosphate. SMS has 2 isoforms: SMS1 and SMS2. Although both enzymes catalyze the same reactions, their subcellular localizations are different: SMS1 is found in the trans-Golgi apparatus, whereas SMS2 is predominantly found in the plasma membranes. 1 It is conceivable that different cellular localizations could yield different consequences, in terms of sphingolipid metabolism and its related atherogenesis. We found that Sms2 deficiency significantly decreases SM levels in the blood, liver, and macrophages, but has only a marginal influence on other sphingolipid levels, 2 and Sms2 total deficiency decreases atherosclerosis in mice. 3 Although we have reported that macrophage Sms2 deficiency has antiatherogenic properties, SMS2 is only responsible for ≈16% of total SMS activity in macrophages. 4 Thus, the consequences of Sms deficiency in macrophages are still largely unknown.
Macrophage toll-like receptors (TLRs) are critically involved in inflammatory responses. Lipid rafts appear to provide a platform for the interaction of TLRs with their ligands in macrophages, [5] [6] [7] [8] initiating nuclear factor (NF)-κB, mitogen-activated protein (MAP) kinase activation, thus leading to inflammatory responses. TLR4 has been shown to play a role in early atheroma development. 9 It is also conceivable that fundamental changes in the sphingolipid levels of the plasma membranes in Sms1 knockout (KO) would influence the function of these proteins and alter inflammatory responses.
In the present study, we examined the effect of Sms1 deficiency on plasma, liver, and macrophage sphingolipid metabolism. Moreover, we examined macrophage-mediated Objective-Sphingomyelin synthase (SMS) catalyzes the conversion of ceramide to sphingomyelin and sits at the crossroads of sphingolipid biosynthesis. SMS has 2 isoforms: SMS1 and SMS2. Although they have the same SMS activity, they are different enzymes with distinguishable subcellular localizations and cell expression patterns. It is conceivable that these differences could yield different consequences, in terms of sphingolipid metabolism and its related atherogenesis. Methods and Results-We created Sms1 gene knockout mice and found that Sms1 deficiency significantly decreased plasma, liver, and macrophage sphingomyelin (59%, 45%, and 54%, respectively), but only had a marginal effect on ceramide levels. Surprisingly, we found that Sms1 deficiency dramatically increased glucosylceramide and GM3 levels in plasma, liver, and macrophages (4-to 12-fold), whereas Sms2 deficiency had no such effect. We evaluated the total SMS activity in tissues and found that Sms1 deficiency causes 77% reduction in SMS activity in macrophages, indicating SMS1 is the major SMS in macrophages. Moreover, Sms1-deficient macrophages have a significantly higher glucosylceramide synthase activity. We also found that Sms1 deficiency significantly attenuated toll-like 4 receptor-mediated nuclear factor-κB and mitogen-activated protein kinase activation after lipopolysaccharide treatment. To evaluate atherogenicity, we transplanted Sms1 knockout mouse bone marrow into low-density lipoprotein receptor knockout mice (Sms1
). After 3 months on a western diet, these animals showed a significant decrease of atherosclerotic lesions in the root and the entire aorta (35% and 44%, P<0.01, respectively) and macrophage content in lesions (51%, P<0.05), compared with wild-type→Ldlr -/-mice. Conclusion-Sms1 deficiency decreases sphingomyelin, but dramatically increases the levels of glycosphingolipids.
Atherosclerosis in Sms1 
Methods
See the online-only Data Supplement for expanded Methods for: Creation of Sms1 KO mice, bone marrow-derived macrophage isolation and culture, lipid analyses by LC/MS/MS, 10 lysenin treatment and cell mortality measurement, 2 SMS activity assay, 2,11 glucosylceramide synthase activity assay, cell surface receptor analysis by fluorescence-activated-cell sorter, Western blot analysis, bone marrow transplantation to replace peripheral macrophages, immunostaining of macrophages in the plaque, and statistical analysis.
Results

Sms1 KO Mouse Preparation
We generated Sms1 KO mice by deleting part of exon 1, which contains the translation initiation codon ATG. This approach created an Sms1 null mouse allele ( Figure 1A) , as shown by Southern blot ( Figure 1B ). Real-time polymerase chain reaction demonstrated that there is no Sms1 expression in the liver and macrophages ( Figure 1C ). However, Sms1 deficiency does not influence Sms2 expression levels ( Figure 1D ).
Sms1 deficiency dramatically decreases macrophage SMS activity (77%, P<0.001) and produces a smaller but still significant reduction in liver SMS activity (15%, P<0.05) ( Figure 1E ). On the other hand, Sms2 deficiency dramatically decreases liver SMS activity (80%, P<0.001) and produces a smaller but once again significant reduction in macrophage SMS activity (16%, P<0.05) ( Figure 1F ). These results suggest that SMS1 is the major isoform in macrophages, whereas SMS2 is the major one in the liver. Moreover, Sms1 deficiency decreases brain, spleen, and lung SMS activity, whereas Sms2 deficiency decreases small intestine and kidney SMS activity ( Figure  I in the online-only Data Supplement).
Both Sms1 and Sms2 Deficiencies Decrease SM Levels
Sms1 deficiency dramatically increases glyco sphingolipid levels, but that of Sms2 does not. We used enzymatic assays to measure plasma lipid levels in Sms1 KO and control animals and found no significant changes in total cholesterol, phospholipids, or triglycerides ( Table  I in MS to measure SM, ceramide, sphingosine-1-phosphate, hydroxyceramide, glucosylceramide, GM3, and phosphatidylcholine levels in mouse plasma. We found, as expected, significant decreases in plasma SM levels (52%, P<0.001) (Table) . Unlike the results with Sms2 KO mice (Table) , 12 plasma ceramide levels were not different in Sms1 KO mice compared with controls. To our surprise, we also found that both glucosylceramide and GM3 were dramatically increased (7-fold and 6-fold, respectively) in Sms1 KO mouse plasma, but no such phenotype was observed in Sms2 KO animals (Table) . Other tested sphingolipids showed no significant changes.
It is known that the liver is one of the major organs for the production of SM-rich and atherogenic apolipoprotein B-containing lipoproteins. 13 Because Sms1 KO mice showed a decrease in plasma SM levels, we next sought to measure sphingolipids in the liver. Although Sms1 is not a major isoform in the liver, its deficiency still significantly decreased liver SM levels (36%, P<0.05) ( Table) . Interestingly, liver ceramide levels were significantly decreased (26%, P<0.05) rather than increased. Glucosylceramide and GM3 again showed a dramatic increase (3.8-fold and 5.5-fold, respectively) compared with controls (Table) .
Macrophages are the most prominent cell types in atherosclerotic lesions and are associated with 1 hallmark of the disease: inflammation. 13, 14 Because SMS1 is the major SMS in macrophages, it is important to study the consequences of Sms1 deficiency in relation to atherosclerosis. Sms1 deficiency significantly decreased macrophage SM levels (70%, P<0.0001) (Table) . Macrophage ceramide levels were not significantly changed. Glucosylceramide and GM3 again showed dramatic increases (12-fold and 7-fold, respectively) compared with controls (Table) .
To determine whether Sms1 deficiency affects membrane levels of SM, we used lysenin that recognizes SM only when it forms aggregates or microdomains in the plasma membranes, subsequently lyzing the cells. Therefore, lysenin-mediated cell mortality could indirectly reflect SM levels in the plasma membranes. As indicated in Figure 2A , Sms1 −/− macrophages, red blood cells, and hepatocytes showed significantly less sensitivity to lysenin-mediated cytolysis than control cells. This implies that Sms1 deficiency significantly decreases SM levels in macrophage and other cell plasma membranes.
We also isolated plasma membranes from wild-type (WT) and Sms1 −/− macrophages and performed Western blot to check the purity of the isolated plasma membranes. As shown in Figure II in the online-only Data Supplement, plasma membrane markers (Na + /K + ATPase) were well detected. But no mitochondrial marker (cytochrome C) could be found in the plasma membrane fraction, indicating that the plasma membrane preparation had achieved a satisfactory state of purity. We then used LC/ESI/MS/MS to measure plasma membrane sphingolipid levels. As shown in Figure 2B and 2C, Sms1 −/− macrophage plasma membranes displayed significantly less SM (65%, P<0.001) and significantly more glucosylceramide (8.5-fold, P<0.0001) and GM3 (6.2-fold, P<0.0001). However, they exhibited no differences in ceramide, cholesterol, or phosphatidylcholine levels compared with controls.
To investigate the mechanism of glucosylceramide accumulation, we incubated macrophages with N-(7-nitrobenz-2-oxa-1,3-diazol-4yl) (NBD)-labeled ceramide and measured NBD-glucosylceramide levels in the medium. We found that Sms1 deficiency causes significantly more NBD-glucosylceramide accumulation in the medium (2.75-fold, P<0.001) ( Figure 2D and 2E) , suggesting Sms1-deficient macrophages have significantly higher glucosylceramide synthase activity than controls. We also performed Western blot analysis for glucosylceramide synthase and found that it was increased (Figure III in the onlineonly Data Supplement). Moreover, we found that the production of NBD-SM is negligible during the 1-hour incubation ( Figure 2D and 2F), suggesting, again, that SMS1 is the major SMS in macrophages.
To investigate the effect of membrane SM directly, we examined whether exogenous SM supplementation could change the inflammatory properties of WT macrophages. We used lysenin assay to evaluate cell membrane SM levels and found that the exogenous supplementation of SM in culture increased the sensitivity of macrophages in response to lysenin-mediated cell death ( Figure IVA in the online-only Data Supplement). More importantly, SM supplementation could promote interleukin-6 (IL-6) production in response to LPS stimulation (10 ng/mL, 16 hours) in a dose-dependent fashion ( Figure IVB in the online-only Data Supplement). We also supplemented macrophages with different concentrations of glucosylceramide and GM3, and then measured IL-6 levels in the culture medium after LPS treatment. We found that neither of them has any effect ( Figure IVC and IVD in the online-only Data Supplement). Thus, our data support that reduced membrane SM levels resulting 
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Value, mean±SD, n=6. *P<0.01. SM indicates sphingomyelin; PC, phosphatidylcholine; Cer, ceramide; DHCer, dihydroceramide; Glycer, glucosylceramide; Sph, sphingosine; S1P, sphingosine-1-phosphate; Sa1P, sphinganine-1-phosphate; SMS, sphingomyelin synthase; KO, knockout.
from Sms1 deficiency caused the blunted inflammatory response of the macrophages.
Sms1-Deficient Macrophages Attenuate NF-κB and MAP Kinase Activation
To determine the impact of macrophage Sms1 deficiency on macrophage-mediated inflammation, LPS-induced MAP kinase and NF-κB activation in Sms1 KO macrophages were compared with those of controls. As shown in Figure 3 , starting 15 minutes after LPS (10 ng/mL) treatment, Sms1 KO macrophages displayed significantly decreased levels of all 3 phosphorylated MAP kinases (phospho-p42/44, phospho-JUK, and phospho-p38), whereas total protein levels were not significantly altered ( Figure 3A-3D) . We also measured cytoplasmic NF-κB inhibitor-α, which must be degraded for NF-κB to become activated, and found that its degradation was attenuated ( Figure 3A and 3E) . These results indicate that Sms1 deficiency diminishes LPS-mediated macrophage MAP kinase and NF-κB activation.
We then sought to investigate LPS-induced cell surface recruitment of TLR4 and its coreceptor MD2, a consequence of signaling upstream of NF-κB activation. 15 Fluorescence-activated cell sorter analysis showed that, after LPS stimulation, Sms1 KO macrophages contained fewer TLR4-MD2 complexes on the cell surfaces than control macrophages ( Figure 3F and 3G ). This result indicates that Sms1 is essential for LPS-induced cell surface TLR4-MD2 complex recruitment.
We also sought to determine the impact of macrophage Sms1 deficiency on macrophage proinflammatory cytokine production, which is downstream of MAP kinase and NF-κB activation. We performed an ex vivo study using LPS to stimulate cultured macrophages from both WT and Sms1 KO mice. We found that Sms1 deficiency significantly attenuates LPS-mediated IL-6 and tumor necrosis factor-α secretion from macrophages compared with controls ( Figure 4A and 4B ). In line with these findings, we also discovered that plasma IL-6 and tumor necrosis factor-α levels in Sms1 KO mice are significantly decreased after LPS stimulation ( Figure  4C and 4D) , suggesting that Sms1 deficiency in macrophages results in less sensitivity to LPS-mediated inflammation. Because both IL-6 and tumor necrosis factor-α levels were very low without LPS treatment, we only measured monocyte chemotactic protein-1, a chemokine involved in inflammation, and found that Sms1 KO mice have significantly less monocyte chemotactic protein-1 in the circulation ( Figure 4E ). Moreover, Sms1 deficiency also significantly attenuates LPS-mediated monocyte chemotactic protein-1 secretion from macrophages ( Figure 4F ).
We also measured macrophage apolipoprotein A-I-and high-density lipoprotein-mediated cholesterol efflux, and we did not find significant changes between the Sms1 KO and WT macrophages ( Figure  V in the online-only Data Supplement).
Macrophage-Specific Sms1 KO Mouse Preparation and Atherosclerosis Evaluation
Twenty-six Ldlr -/-mice were lethally irradiated. After 3 hours, half the animals were transplanted with Sms1 -/-mouse bone marrow cells (Sms1 -/-→Ldlr -/-) and the other half with WT ones (WT→Ldlr -/-). We monitored the process of cell replacement by polymerase chain reaction, using genomic DNA from mouse white blood cells as a template, and measured them 8 weeks after transplantation.
As expected, bone marrow-derived Sms1 
001). Sms1
-/-→Ldlr -/-macrophages had significantly less SM levels and significantly higher glucosylceramide and GM3 levels compared with controls (Table II in the online-only Data Supplement). We also found that Sms1
-/-→Ldlr -/-macrophages secreted significantly less IL-6 after LPS stimulation compared with WT→Ldlr -/-controls ( Figure VII in the online-only Data Supplement). At this point, the rest of the animals were switched to a western diet (0.15% cholesterol, 20% saturated fat) for 3 months. We measured plasma lipid levels (cholesterol, SM, phosphatidylcholine, and triglycerides) in these animals and found no significant changes (Table III in the online-only Data Supplement). There was no significant difference in blood cell counts between WT and Sms2 KO mice (Table IV in To evaluate the impact of macrophage Sms1 deficiency on atherogenesis, we dissected mouse aortas and photographed them. We also measured proximal and whole aortic lesion areas. After 3 months on a western diet, we found that all mice (18/18) had lesions in the aortic arch. However, the Sms1 -/-→Ldlr -/-animals had observably smaller ones than the WT→Ldlr -/-animals ( Figure 5A ). We also found that the Sms1 -/-→Ldlr -/-animals had 45% less lesion area in the whole aorta ( Figure 5B and 5C) and 35% less in the proximal aorta ( Figure 5D and 5E) compared with WT→Ldlr -/-mice. These differences were highly significant (P<0.001 and P<0.01, respectively).
We performed immunohistochemistry for macrophages and found that they were significantly decreased in Sms1 -/-→Ldlr -/-mice compared with controls ( Figure 5F and 5G). We determined the blood cell counts for both Sms1 -/-→Ldlr -/-and WT→Ldlr -/-mice and found no significant changes (Table IV in 
Discussion
While we were preparing our Sms1 KO mice, Yano et al 16 reported that their Sms1 KO mice exhibited moderate neonatal lethality, reduced body weight, loss of fat tissue mass, β-cell mitochondrial dysfunction, and insulin secretion inhibition. We also found that the targeted allele was not segregated in a Mendelian fashion. Homozygous crosses did not yield viable progeny. We did not observe body weight reduction and the reason is unknown. In this study, we focused on plasma and tissue sphingolipid metabolism and examined atherosclerosis in Ldlr -/-mice that were transplanted with Sms1-deficient bone marrows. All these aspects were not investigated by the previous study. 16 In this study, we have demonstrated for the first time that disruption of the Sms1 gene caused: (1) a significant reduction of SM levels in the plasma, macrophages, and liver, and marginal changes in ceramide levels; (2) a dramatic increase of glycosphingolipid levels in the plasma, macrophages, and liver; and (3) a significant reduction of macrophage MAP kinase and NF-κB activation after LPS treatment. Finally and most importantly, Sms1 deficiency in bone marrow-derived cells led to a decrease in atherosclerosis in Ldlr -/-mice fed a western diet for 3 months.
The first key finding of this study is that SMS1, like SMS2, 11 contributes importantly to the de novo SM biosynthesis and SM levels in plasma and cell membranes. In support of our data, another report has indicated that both SMS1 and SMS2 are required for SM homeostasis and growth in human HeLa cells.
17 SMS1 and SMS2 activity are coexpressed in a variety of tissues and cells ( Figure I in the online-only Data Supplement). SMS1 is the major SMS in macrophages ( Figure 1E ), whereas SMS2 is the major one in the liver ( Figure 1F ). The second key finding is that Sms1 deficiency dramatically increased glycosphingolipid levels, but that of Sms2 did not. The most common inherited defect in glycosphingolipid breakdown is Gaucher disease, an autosomal-recessive disorder arising from mutations in the gene encoding the lysosomal acid β-glucosidase 1 (GBA1).
18 GBA1-deficient mice have a Gaucher disease-like phenotype. 19 GBA2 is a second glucosylceramidase located in the endoplasmic reticulum rather than the lysosome. Glucosylceramides have been found to accumulate in multiple tissues from GAB2 KO mice, leading to decreased fertility and formation of abnormal sperm. 20 We examined the bone marrow and spleens from Sms1 KO mice and found no glucosylceramide accumulation or giant monocytes (typical cells in Gaucher disease) (data not shown). 20 We also measured glucosidase activity and found no differences between the KO and control mice (data not shown). However, Sms1 deficiency significantly increased glucosylceramide synthase activity in macrophages ( Figure 2D and 2E) . We believe that glucosylceramide synthase is upregulated to avoid ceramide accumulation in Golgi complex.
The different locations of SMS1 and SMS2 may explain why Sms1 deficiency accumulates glycosphingolipids in the tissues, but that of Sms2 does not. On the one hand, SMS1, 1, 21 glucosylceramide synthase, 22 and ganglioside synthases 23 are located in the same Golgi compartment. Sms1 deficiency promotes glucosylceramide and ganglioside accumulation by providing more substrate, ie, ceramide. The Golgi-accumulated glycosphingolipids might influence the lipid levels in other organelles, plasma membranes, and blood through vesicle trafficking, fusion, and secretion. On the other hand, SMS2 is located in cell plasma membranes where there are no glucosylceramide synthase or ganglioside synthase activities, so Sms2 deficiency has no impact on glycosphingolipid accumulation.
It has been reported that the interaction of SM, cholesterol, and glycosphingolipids drives the formation of plasma membrane rafts.
24 SMS1 has been implicated in the regulation of lipid raft SM level and raft functions such as Fas receptor clustering, 25 endocytosis, and apoptosis. 26 In this study, we observed that Sms1 deficiency not only reduces membrane SM levels significantly but also increases those of membrane glycosphingolipids dramatically ( Figure 2C ). The question is whether these changes influence macrophage inflammatory responses.
Sms1 deficiency has anti-inflammatory properties. Accumulation of glycosphingolipids may contribute to this property. It has been shown that dietary gangliosides decrease cholesterol content, caveolin expression, and inflammatory mediators in rat intestinal cell lipid rafts. 27 In contrast, some reports have indicated that glycosphingolipids are potential atherogenic lipids. 28 Thus, in general, the relationship between glycosphingolipid metabolism and inflammation is still largely unknown. In this study, we found that Sms1 deficiency, like that of Sms2, attenuates NF-κB and MAP kinase activations. Our lipid supplement study indicated that SM but not glucosylceramide or GM3 enrichment on plasma membrane promotes inflammatory responses in macrophages after LPS stimulation ( Figure IV in the online-only Data Supplement).
The third key finding is that macrophage Sms1 deficiency decreases the atherogenic plaque size (Figure 5A-5E ). In general, macrophage Sms1 deficiency yields a phenotype similar to that of Sms2 deficiency in terms of atherogenicity. This is probably due to the reduction of SM in macrophages and macrophage plasma membranes, which reduces inflammatory responses. Although there has been a report indicating that inhibition of glucosylceramide synthase reduces atherosclerosis in mice, this has not been confirmed by another investigation. 29 In this study, we found that Sms1 deficiencymediated macrophage glycosphingolipid accumulation does not have proatherogenic properties ( Figure 5 ).
Ceramide can be generated through the de novo pathway 30 and the sphingomyelinase pathway. 31 Roles have been proposed for ceramide in atherogenesis, including mediating apoptosis 32 and inflammatory cytokine production. 33 However, Sms1 deficiency has no effect on ceramide levels (Table; Figure 2C ). Thus, Sms1 deficiency-mediated antiatherogenic effects might not be related to ceramide levels.
Macrophages cannot limit the uptake of cholesterol, and therefore depend on cholesterol efflux pathways for preventing their transformation into foam cells. Several ATP-binding cassette transporters 34 facilitate the efflux of cholesterol from macrophages. It is conceivable that fundamental changes of sphingolipid levels in plasma membranes could influence the function of these proteins, altering cholesterol efflux. Indeed, enhanced apolipoprotein A-I-dependent cholesterol efflux by ATP-binding cassette protein A1 from SM-deficient Chinese hamster ovary cells has been reported. 35 We also reported that Sms2 deficiency decreases macrophage cholesterol efflux. 4 However, we did not find changes in cholesterol efflux between the Sms1 KO and WT macrophages ( Figure V in the online-only Data Supplement).
In conclusion, Sms1 deficiency causes blunted NF-κB and MAP kinase responses to inflammatory/immunological stimuli and reduces atherosclerosis in a mouse model. Specific inhibition of SMS1 in macrophages may very well provide an antiatherosclerotic phenotype in which inflammatory responses can be curtailed. 
